Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 594

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 3
Chunk 594
---
 and other offering
    expenses in the amount of approximately $0.25 million. In February 2025, the Company filed a registration statement to register the
    resale by the investors of the shares of common stock and shares of common stock issuable upon exercise of the January 2025 Warrants.
    The registration statement was declared effective on February 11, 2025. In addition, in connection with the January 2025 Offering,
    the Company issued to the placement agent and its designees warrants to purchase an aggregate of 147,656 shares of common stock at
    an exercise price of $1.175. The placement agent warrants are exercisable six months from the date of issuance and expire on the
    fifth anniversary of the issue date. The fair value of a warrant to purchase one share of common stock that was issued to the placement
    agent was $0.74.

    F-13

    f.
    On February 12, 2025, the
    Company entered into a Standby Equity Purchase Agreement (the “SEPA”) with
    YA II PN, LTD., a Cayman Islands exempt limited company (“Yorkville”), which provides that, upon the terms and subject
    to the restrictions and satisfaction of the conditions in the SEPA, Yorkville is committed to purchase up to an aggregate of $20.0
    million of the Company’s shares of common stock over a 36-month period. At the Company’s option, the shares of common
    stock would be purchased by Yorkville from time to time at a price equal to 97% of the lowest of the three daily VWAPs during a three
    consecutive trading day period commencing on the date that the Company, subject to certain limitations, delivers a notice to Yorkville
    that the Company is committing Yorkville to purchase such shares of common stock. The Company may also specify a certain minimum
    acceptable price per share in each advance. The Company will control the timing and amount of sales of the Company’s shares
    to Yorkville. As consideration for Yorkville’s irrevocable commitment to purchase shares of the Company’s common stock
    upon the terms of and subject to restrictions and satisfaction of the conditions set forth in the SEPA, upon execution of the SEPA,
    the Company issued to Yorkville 305,960 shares of common stock, as commitment shares. Under
    the applicable Nasdaq Rules and pursuant to the SEPA, in no event may the